A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.
Inclusion Criteria:
Exclusion Criteria:
Clinical.Trials@bms.com855-907-3286
Phoenix, Arizona 85054, United States
Bordeaux, Aquitaine 33076, France
Münster, North Rhine-Westphalia 48149, Germany
Chuo-ku, Tokyo 104-0045, Japan
Salamanca, 37007, Spain
626-218-2405
813-745-4294
617-632-6844
917-887-8514
13683398726
13970038386
33556333333
33320445713
33142114507
+33145178242
+33675926918
33142499236
33531156351
+492518346010
4968411615000
493419713841
+49 30 9401-12104
+491631751277
0552731111
+31433877026
050-3616161
607847416
34932746000X4975
34915868394
34 948 396 297
349155048002218
34923291100
41918118931
41612655074
+41795532406